Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation
Advanced Science · 2026
DOI: 10.1002/advs.77450 ↗At a glance
Übersichtsarbeit in Advanced Science, 2026. Written by Jianv Jiang and 3 co-authors. Institution: Key Lab of Artificial Organs and Computational Medicine, Institute of Translational Medicine, Shulan International Medical College, Zhejiang Shuren U…. Major MEDLINE topics: Drug Delivery Systems, Precision Medicine, Neoplasms, Radiotherapy. 198 references. The full text is freely available (open access, CC BY 4.0). Funded by: Natural Science Foundation of Hangzhou, Zhejiang Shuren University Research Project, cientific Research Start-up Funding Project of Sir Run Run Shaw Hospital of Zhejiang University.
Abstract (original language)
Radiotherapy‐triggered drug delivery systems (RDDS) promise to integrate the spatial precision of ionizing radiation with controllable pharmacological activation. However, clinical translation remains constrained by its reliance on supra‐clinical irradiation doses. Here, we present a unifying framework redefining RDDS through two distinct paradigms: structural disassembly and molecular actuation. We delineate their radiochemical foundations, highlighting reductive and electron‐driven mechanisms as more robust and tumor‐selective than stochastic reactive oxygen species‐mediated pathways. Furthermore, we position radiation‐driven gas therapy as a distinct modality based on in situ molecular generation. Critically, we identify the dose–response mismatch between radiolytic chemistry and clinical radiation as the central translational bottleneck. To overcome this, we propose a design paradigm centered on highly predictable, dose‐matched activation, where mechanisms directly coupling radiation energy to molecular transformation offer superior predictability. Finally, we explore the integration of RDDS with imaging and artificial intelligence to create closed‐loop, feedback‐controlled systems. This review establishes a conceptual and translational roadmap, envisioning the evolution of radiotherapy from a purely cytotoxic modality into a programmable actuator for precision oncology.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Key Lab of Artificial Organs and Computational Medicine, Institute of Translational Medicine, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, People's Republic of China.
- Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
- Zhejiang Key Laboratory of Cardiovascular Intervention and Precision Medicine, Hangzhou, People's Republic of China.
- Engineering Research Center for Cardiovascular Innovative Devices of Zhejiang Province, Hangzhou, People's Republic of China.
ORCID profiles: Wenjing Sun
Funding
- Natural Science Foundation of Hangzhou
- Zhejiang Shuren University Research Project
- cientific Research Start-up Funding Project of Sir Run Run Shaw Hospital of Zhejiang University
Cite
APA
Jiang, J., Zhang, T., Dong, J., & Sun, W. (2026). Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation. Advanced Science. https://doi.org/10.1002/advs.77450
Vancouver
Jiang J, Zhang T, Dong J, Sun W. Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation. Advanced Science. 2026. doi:10.1002/advs.77450
BibTeX
@article{Jiang2026,
author = {Jiang, Jianv and Zhang, Tanfeng and Dong, Junliang and Sun, Wenjing},
title = {Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.77450}
}
EUVIMED